Bluejay Diagnostics, Inc. 8-K

What Happened

• On April 7, 2026, Bluejay Diagnostics, Inc. announced a press release providing an update on patient enrollment in its ongoing SYMON‑II clinical trial. The disclosure was made under Item 7.01 (Regulation FD Disclosure) of Form 8‑K.

Key Details

• Company: Bluejay Diagnostics, Inc. (BJDX).
• Date of disclosure: April 7, 2026.
• Subject: Status update on patient enrollment in the SYMON‑II clinical trial.
• Filing: Press release attached as Exhibit 99.1 to the Form 8‑K.

Why It Matters

• Enrollment progress in a clinical trial is a material operational milestone for a diagnostics company; it can affect trial timelines, potential regulatory submissions, and investor expectations.
• This 8‑K contains the company’s public update only; it does not report financial results, management changes, or new guidance in this filing. Investors should review the attached press release for specifics and watch for future filings or announcements with enrollment numbers or trial milestones.